公开(公告)号：WO2005113059A2

公开(公告)日：2005-12-01

申请号：PCT/US2005/018331

申请日：2005-05-24

Applicant: V.I. TECHNOLOGIES, INC. ,  THE GOVERMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  SALZWEDEL, Karl ,  LI, Feng ,  WILD, Carl T. ,  ALLAWAY, Graham P. ,  FREED, Eric O.

Inventor： SALZWEDEL, Karl ,  LI, Feng ,  WILD, Carl T. ,  ALLAWAY, Graham P. ,  FREED, Eric O.

IPC: A61M37/00

CPC classification number: C07K14/005 ,  A61K38/162 ,  C07K16/1054 ,  C12N7/00 ,  C12N2740/16222 ,  G01N33/56988 ,  G01N2500/02

Abstract: Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

Abstract translation: 公开了通过破坏来自CA-间隔肽1（SP1）蛋白前体（p25）的病毒Gag衣壳（CA）蛋白（p24））的加工来抑制HIV-1复制。 含有Gag p25蛋白突变的氨基酸序列，突变导致二甲基琥珀酰桦树酸或二甲基琥珀酰基桦木醇处理p25至p24的抑制作用降低，编码这种突变序列的多核苷酸和选择性结合这种突变序列的抗体是 也包括在内。 包括抑制，抑制化合物的方法和发现靶向HIV Gag蛋白的蛋白水解加工的抑制性化合物的方法。 在一个实施方案中，这些化合物通过结合Gag而不是蛋白酶抑制HIV蛋白酶与Gag的相互作用。 在另一个实施方案中，在Gag蛋白水解切割位点区域中含有突变的病毒或重组蛋白质可用于筛选测定以鉴定靶向蛋白水解加工的化合物。

公开(公告)号：WO2004065008A1

公开(公告)日：2004-08-05

申请号：PCT/US2004/001042

申请日：2004-01-15

Applicant: V.I. TECHNOLOGIES, INC. ,  PURMAL, Andrei ,  TABATADZE, David

Inventor： PURMAL, Andrei ,  TABATADZE, David

IPC: B01J39/04

CPC classification number: A61K35/14 ,  A01N1/0215 ,  A61K35/18 ,  A61L2/0011 ,  A61L2/0082 ,  B01D63/00 ,  B01J39/05 ,  B01J39/07

Abstract: Methods for removal of positively charged microbicidal compound, in particular an aziridino compound, from composition such as a blood product by contacting the composition with a cation exchange resin allowing the positively charged compound to bind to the resin and then separating the resin-bound compound from the composition.

Abstract translation: 通过使组合物与阳离子交换树脂接触使得带正电的化合物与树脂结合，然后将树脂结合的化合物从...中分离出来，从组合物如血液制品中除去带正电的杀微生物化合物，特别是氮丙啶基化合物的方法 组成。

公开(公告)号：WO2003066806A3

公开(公告)日：2003-08-14

申请号：PCT/US2002/035501

申请日：2002-11-05

Applicant: V.I. TECHNOLOGIES, INC. ,  CHAPMAN, John ,  ALFORD, Bernadette ,  PURMAL, Andrei, A. ,  ZAVIZION, Boris

Inventor： CHAPMAN, John ,  ALFORD, Bernadette ,  PURMAL, Andrei, A. ,  ZAVIZION, Boris

IPC: C12N7/06

Abstract: Methods are provided for treatment of diseases. The methods include preventing or inhibiting transcription and/or replication of a nucleic acid molecule by administering to a subject in need of such treatment an effective amount of one or more aziridino compounds. Pharmaceutical compositions comprising the one or more aziridino compounds also are provided.

公开(公告)号：WO2002067956A2

公开(公告)日：2002-09-06

申请号：PCT/US2002/001878

申请日：2002-01-22

Applicant: V.I. TECHNOLOGIES, INC. ,  CHAPMAN, John ,  PURMAL, Andrei ,  HOPE, James

Inventor： CHAPMAN, John ,  PURMAL, Andrei ,  HOPE, James

IPC: A61K35/14

CPC classification number: G01N33/6896 ,  A61K35/18 ,  A61L2/0011 ,  A61L2/0017 ,  A61L2/0082

Abstract: The invention is based on the discovery of a method for removing an analyte from blood cells that results in a preparation of blood cells in which the level of the residual analyte is significantly reduced in the cell population. The method can be performed on large volume blood cell suspensions, and the cells prepared in this manner remain viable following prolonged storage and are suitable for therapeutic use, e.g. in transfusion applications. A preferred blood cell preparation is one that includes a red blood cell (RBC) population.

Abstract translation: 本发明基于从血细胞中去除分析物的方法的发现，其导致血细胞的制备，其中细胞群体中残留分析物的水平显着降低。 该方法可以在大体积血细胞悬浮液上进行，并且以这种方式制备的细胞在延长的储存后保持存活并且适合于治疗用途，例如， 在输血应用中。 优选的血细胞制剂是包含红细胞（RBC）群体的细胞制剂。

公开(公告)号：WO2002099073A2

公开(公告)日：2002-12-12

申请号：PCT/US2002/017861

申请日：2002-06-06

Applicant: V.I. TECHNOLOGIES, INC ,  LAZO, Aristides ,  OHAGEN, Asa

Inventor： LAZO, Aristides ,  OHAGEN, Asa

IPC: C12N

CPC classification number: G01N33/5091 ,  G01N33/5008 ,  G01N33/5094 ,  G01N33/56983 ,  G01N33/56988 ,  G01N2333/02 ,  G01N2333/161 ,  G01N2333/18

Abstract: Disclosed is a method for identifying levels of an infectious virus in a cell population by comparing the level of a viral gene product in a first population of cells cultured in the presence of the virus with the level of the viral gene product in a second population of cells cultured under conditions that inhibit replication of the virus, e.g., cells that are cultured in the presence of an inhibitor of replication of the virus.

Abstract translation: 公开了一种通过比较在存在病毒的情况下培养的第一群细胞中的病毒基因产物的水平与第二群体中病毒基因产物的水平来鉴定细胞群体中感染性病毒水平的方法 在抑制病毒复制的条件下培养的细胞，例如在病毒复制抑制剂存在下培养的细胞。

公开(公告)号：WO2005002570A1

公开(公告)日：2005-01-13

申请号：PCT/US2004/019986

申请日：2004-06-22

Applicant: V.I. TECHNOLOGIES, INC. ,  ZAVIZION, Boris ,  PURMAL, Andrei ,  SEREBRYANIK, Diana

Inventor： ZAVIZION, Boris ,  PURMAL, Andrei ,  SEREBRYANIK, Diana

IPC: A61K31/396

CPC classification number: A61L2/0088 ,  A61K31/396 ,  A61L2/18 ,  C07C211/15 ,  C07D203/08 ,  C07D203/12 ,  Y02A50/414

Abstract: The invention features a method for inactivating parasites in biological compositions. The method includes contacting the biological composition with an aziridino compound under parasite inactivating conditions.

Abstract translation: 本发明的特征在于灭活生物组合物中的寄生虫的方法。 该方法包括在寄生虫灭活条件下使生物组合物与氮丙啶基化合物接触。

公开(公告)号：WO2006002248A1

公开(公告)日：2006-01-05

申请号：PCT/US2005/022085

申请日：2005-06-20

Applicant: V.I. TECHNOLOGIES, INC. ,  THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ,  NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES ,  ALLAWAY, Graham P. ,  WILD, Carl T. ,  KASHIWADA, Yoshiki ,  LEE, Kuo-Hsiung

Inventor： ALLAWAY, Graham P. ,  WILD, Carl T. ,  KASHIWADA, Yoshiki ,  LEE, Kuo-Hsiung

IPC: C07J53/00

CPC classification number: C07J53/00 ,  A61K31/56 ,  A61K45/06 ,  A61K2300/00

Abstract: Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have Formula I as described herein, or pharmaceutically acceptable salts thereof; wherein R 1 is a C 2 -C 20 substituted or unsubstituted carboxyacyl or ester thereof; R 2 is hydrogen, halogen, hydroxyl or -OR 3 , R 3 is C 2 -C 20 substituted or unsubstituted carboxyacyl; and R 4 is hydrogen or C(C 6 H 5 ) 3 ; wherein the dashed line represents an optional double bond between C20 and C29.

Abstract translation: 已经发现根据本发明的桦木醇和二氢甜菜碱酰基衍生物具有有效的抗HIV活性。 本发明的化合物具有本文所述的式I或其药学上可接受的盐; 其中R 1是C 2 -C 20 - 取代或未取代的羧酰基或其酯; R 2是氢，卤素，羟基或-OR 3，R 3是C 2 -C 3 取代或未取代的羧酰基; 并且R 4是氢或C（C 6 H 5）3 N 3。 其中虚线表示C20和C29之间任选的双键。

公开(公告)号：WO2003093512A1

公开(公告)日：2003-11-13

申请号：PCT/US2003/014363

申请日：2003-05-06

Applicant: V.I. TECHNOLOGIES, INC. ,  PLUNKETT, Kevin ,  PURMAL, Andrei, A. ,  ZAVIZION, Boris ,  CHAPMAN, John

Inventor： PLUNKETT, Kevin ,  PURMAL, Andrei, A. ,  ZAVIZION, Boris ,  CHAPMAN, John

IPC: C12Q1/68

CPC classification number: C07D203/12 ,  C12N7/00 ,  C12N2750/14363

Abstract: This invention relates to methods and compositions for the modification of nucleic acids.

Abstract translation: 本发明涉及用于修饰核酸的方法和组合物。

公开(公告)号：WO2003066806A2

公开(公告)日：2003-08-14

申请号：PCT/US2002/035501

申请日：2002-11-05

Applicant: V.I. TECHNOLOGIES, INC. ,  CHAPMAN, John ,  ALFORD, Bernadette ,  PURMAL, Andrei, A. ,  ZAVIZION, Boris

Inventor： CHAPMAN, John ,  ALFORD, Bernadette ,  PURMAL, Andrei, A. ,  ZAVIZION, Boris

IPC: C12N

CPC classification number: A61K45/06 ,  A61K31/396 ,  Y02A50/463 ,  A61K2300/00

Abstract: Methods are provided for treatment of diseases. The methods include preventing or inhibiting transcription and/or replication of a nucleic acid molecule by administering to a subject in need of such treatment an effective amount of one or more aziridino compounds. Pharmaceutical compositions comprising the one or more aziridino compounds also are provided.

Abstract translation: 为治疗疾病提供了方法。 所述方法包括通过向需要这种治疗的受试者施用有效量的一种或多种氮丙啶基化合物来预防或抑制核酸分子的转录和/或复制。 还提供了包含一种或多种氮丙啶基化合物的药物组合物。

公开(公告)号：WO2002067956A3

公开(公告)日：2002-09-06

申请号：PCT/US2002/001878

申请日：2002-01-22

Applicant: V.I. TECHNOLOGIES, INC. ,  CHAPMAN, John ,  PURMAL, Andrei ,  HOPE, James

Inventor： CHAPMAN, John ,  PURMAL, Andrei ,  HOPE, James

IPC: A61K35/14

Abstract: The invention is based on the discovery of a method for removing an analyte from blood cells that results in a preparation of blood cells in which the level of the residual analyte is significantly reduced in the cell population. The method can be performed on large volume blood cell suspensions, and the cells prepared in this manner remain viable following prolonged storage and are suitable for therapeutic use, e.g. in transfusion applications. A preferred blood cell preparation is one that includes a red blood cell (RBC) population.